| 87.85 1.17 (1.35%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 109.09 | 1-year : | 115 |
| Resists | First : | 93.4 | Second : | 98.45 |
| Pivot price | 89.23  |
|||
| Supports | First : | 85.22 | Second : | 70.9 |
| MAs | MA(5) : | 87.5 |
MA(20) : | 90.43 |
| MA(100) : | 91.9 |
MA(250) : | 89.8 |
|
| MACD | MACD : | -2 |
Signal : | -1.8 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 18 |
| RSI | RSI(14): 40.1 |
|||
| 52-week | High : | 107.44 | Low : | 67.07 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IRMD ] has closed above bottom band by 34.3%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 88 - 88.53 | 88.53 - 89.04 |
| Low: | 85.08 - 85.7 | 85.7 - 86.3 |
| Close: | 86.88 - 87.81 | 87.81 - 88.7 |
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Thu, 20 Aug 2026
IRADIMED (NASDAQ:IRMD) Could Be A Buy For Its Upcoming Dividend - 富途牛牛
Wed, 19 Aug 2026
Rice Hall James & Associates LLC Invests $2.91 Million in iRadimed Corporation $IRMD - MarketBeat
Tue, 18 Aug 2026
iRadimed (NASDAQ:IRMD) Shares Cross Below 200 Day Moving Average - Time to Sell? - MarketBeat
Sun, 09 Aug 2026
IRadimed (IRMD) Q2 2026 Earnings Call Transcript - webull.com
Sun, 09 Aug 2026
IRADIMED CORPORATION (NASDAQ:IRMD) Looks Interesting, And It's About To Pay A Dividend - simplywall.st
Fri, 07 Aug 2026
IRadimed Corporation (IRMD) Stock Analysis: A Look At Its 29% Upside Potential - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 13 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 35.1 (%) |
| Held by Institutions | 61.1 (%) |
| Shares Short | 706 (K) |
| Shares Short P.Month | 682 (K) |
| EPS | 1.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.71 |
| Profit Margin | 26.7 % |
| Operating Margin | 31.2 % |
| Return on Assets (ttm) | 15.5 % |
| Return on Equity (ttm) | 23.5 % |
| Qtrly Rev. Growth | 0.3 % |
| Gross Profit (p.s.) | 5.12 |
| Sales Per Share | 6.75 |
| EBITDA (p.s.) | 2.28 |
| Qtrly Earnings Growth | -9.4 % |
| Operating Cash Flow | 27 (M) |
| Levered Free Cash Flow | 16 (M) |
| PE Ratio | 49.07 |
| PEG Ratio | 0 |
| Price to Book value | 11.39 |
| Price to Sales | 13.01 |
| Price to Cash Flow | 41.4 |
| Dividend | 0.2 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|